Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 2/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.63 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL383785 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 1.00 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL5972612 | 0.99 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL4369589 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL4377553 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL22475009 | 0.92 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL14782966 | 0.92 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2533738 | 0.91 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233573-B1 | A COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2013-10-23 | — | — | EP | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20120195917-A1 | Vaccine Composition Comprising 5'-CAP Modified RNA | OCV Intellectual Capital , LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
| WO-2007001926-A2 | LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | HINT1 923/4885NT5E 2965/4885GSK3A 4436/4885 |
| US-20120195917-A1 | Vaccine Composition Comprising 5'-CAP Modified RNA | RNMT, RNGTT, CAPG | HINT1 1509/4885NT5E 399/4885GSK3A 3542/4885 |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | GGH, GGPS1, GGT1 | HINT1 561/4885NT5E 1073/4885GSK3A 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.